YAP1 TEAD-binding Domain (human, recombinant)

Yes1-associated transcriptional regulator (YAP1) is a transcriptional coactivator and member of the Hippo signaling pathway with roles in development, stem cell maintenance, and tissue homeostasis and regulation.^1,2 It is composed of an N-terminal proline-rich region and TEAD-binding domain, a WW domain, and a C-terminal transactivation domain.¹ YAP1 is ubiquitously expressed and localizes to both the cytoplasm and nucleus. During tissue homeostasis, YAP1 activity is suppressed to maintain stem cell quiescence, but it is de-repressed during injury to facilitate stem cell self-renewal and tissue repair via interaction with various signaling pathways, including Wnt, TGF-β, and EGF.^2,3 YAP1 has both pro- and anti-apoptotic functions attributed to the interaction of its WW domain with the tumor suppressors p63 and p73 and the interaction of its N-terminal domain with TEAD transcription factors, respectively.^4,5 Mutation of YAP1 at serine 127 prevents YAP1 phosphorylation and increases nuclear retention of YAP1, inducing ferroptosis in cancer cells.⁶ Homozygous deletion of Yap1 is embryonically lethal in mice.² Various YAP1 fusion proteins, all of which retain the TEAD-binding domain and exhibit constitutive nuclear localization, are associated with lung adenocarcinoma, cervical carcinoma, breast invasive carcinoma, or skin cutaneous melanoma and with tumor progression.^7,8,9 Cayman’s YAP1 TEAD-binding Domain (human, recombinant) protein can be used for binding assay and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Kodaka, M., and Hata, Y. The mammalian Hippo pathway: Regulation and function of YAP1 and TAZ. Cell Mol. Life Sci. 72(2), 285-306 (2015).

2. Szulzewsky, F., Holland, E.C., and Vasioukhin, V. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Dev. Biol. 475, 205-221 (2021).

3. Wang, Y., Yu, A., and Yu, F.X. The Hippo pathway in tissue homeostasis and regeneration. Protein Cell 8(5), 349-359 (2017).

4. Strano, S., Monti, O., Pediconi, N., et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol. Cell 18(4), 447-459 (2005).

5. Zhao, B., Ye, X., Yu, J., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22(14), 1962-1971 (2008).

6. Dai, C., Chen, X., Li, J., et al. Transcription factors in ferroptotic cell death. Cancer Gene Ther. 27(9), 645-656 (2020).

7. Hu, X., Wang, Q., Tang, M., et al. TumorFusions: An integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 46(D1), D1144-D1149 (2018).

8. Pajtler, K.W., Wei, Y., Okonechnikov, K., et al. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nat. Commun. 10(1), 3914 (2019).

9. Szulzewsky, F., Arora, S., Hoellerbauer, P., et al. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Genes Dev. 34(15-16), 1051-1064 (2020).